Alternatives to Evotec

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Physics-based molecular simulation with AI for drug discovery and materials design.

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

AI drug discovery engine pairing 2M weekly automated lab experiments with a 50+ PB proprietary dataset.

NExTNet pairs an evidence-backed life sciences Copilot with Explorer knowledge maps over a deterministic biomedical ontology.

AI-driven scientific diligence software for pharma BD, biotech and life science investors evaluating in-licensing, M&A and investment

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

Cellino's AI-guided optical bioprocessing automates personalized cell therapy manufacturing on the Nebula™ platform.

SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response

AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Quibim turns MRI, CT and PET scans into regulatory-cleared quantitative imaging biomarkers for prostate, brain, liver, breast and lung.

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

AI protein engineering that optimizes binding, stability, activity, and expression across wet-lab rounds.

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.

Dotmatics Luma Agent: agentic AI for regulated R&D that plans, executes, and documents scientific data analysis

Automated cloud lab for protein validation — binding, expression and thermostability assays with data back in as little as 3 days